Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
evx-03 save search
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
evx-01 first vaccine cancer trial
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 6.58%
H: 14.71%
C: 14.12%
vaccine infection results
United States Supercapacitor Market, Competition, Forecast & Opportunities Report 2023-2028 Featuring Eaton, Maxwell Technologies, TOKIN, Panasonic, Loxus, AVX, ADA Technologies, and Tesla
Published: 2023-11-21 (Crawled : 17:00) - prnewswire.com
PCRFY | News | $9.52 -0.11% 420K
|
n/a
|
| O: 0.85%
H: 0.84%
C: -0.09%
report
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
Published: 2023-11-06 (Crawled : 15:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 5.26%
H: 0.0%
C: -7.5%
evx-01 phase 2
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
Published: 2023-10-31 (Crawled : 15:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 4.81%
H: 27.55%
C: 14.29%
evx-01 vaccine cancer phase 2
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
Published: 2023-07-31 (Crawled : 11:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 3.15%
H: 0.0%
C: 0.0%
vaccine results
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
Published: 2023-06-03 (Crawled : 00:20) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
| Email alert
Add to watchlist
evx-01 melanoma vaccine cancer technology trial
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: -5.59%
H: 5.92%
C: 1.97%
evx-01 vaccine cancer
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
Published: 2023-04-18 (Crawled : 20:00) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: -5.75%
H: 9.76%
C: -5.49%
evx-02 cancer immunotherapy trial
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 0.0%
H: 1.79%
C: -1.82%
evx-02 research meeting biotech vaccine dna association cancer
VIAVI AVX-10K Flight Line Test Set Approved For Use On Boeing Commercial Aircraft
Published: 2023-03-14 (Crawled : 11:00) - prnewswire.com
VIAV | $7.95 -1.49% -1.51% 1.3M
|
Electronic Technology
|
| O: 2.06%
H: 1.92%
C: 1.54%
avx-10 test set commercial approved
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
Published: 2023-01-03 (Crawled : 13:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 17.75%
H: 2.39%
C: -16.75%
evx-01 fda approval study phase 2b
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 1.81%
H: 7.56%
C: 2.67%
evx-02 immunotherapy dna trial results cancer phase 1
Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
Published: 2022-09-21 (Crawled : 10:00) - globenewswire.com
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 71.05%
H: 8.3%
C: -28.31%
evx-01 therapy cancer milestone
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
Published: 2022-06-23 (Crawled : 12:00) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 7.39%
H: 3.17%
C: -2.12%
evx-03 biotech vaccine dna program cancer
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: -0.7%
H: 8.77%
C: -2.81%
evx-02 trial phase 1 biotech iot phase 2 phase 3
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
Published: 2022-01-26 (Crawled : 13:00) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 2.54%
H: 0.0%
C: -11.54%
evx-01 phase 2 phase 2b collaboration biotech iot
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
EVAX | $4.19 -2.78% -0.48% 9.9K
|
Manufacturing
|
| O: 3.91%
H: 0.0%
C: -6.12%
evx-01 keytruda treatment phase 2 clearance trial biotech iot
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
ALPMY | News | $9.53 0.32% -1.11% 690K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -2.82%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.22%
H: 2.27%
C: 1.35%
treatment cancer trial enroll
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.53 0.32% -1.11% 690K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -2.82%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.22%
H: 2.27%
C: 1.35%
treatment cancer trial enroll
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.